Evidence map›Paper›PMID 37076291›Full record

ArticleJournal of neurology, neurosurgery, and psychiatry2023

Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis.

David Leppert, Mitsuru Watanabe, Sabine Schaedelin, Fredrik Piehl, Roberto Furlan, Matteo Gastaldi, Jeremy Lambert, Björn Evertsson, Katharina Fink, Takuya Matsushita and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurology, neurosurgery, and psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 5 countries.

David LeppertDepartment of Neurology, Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland david.leppert@unibas.ch.ORCID 0000-0001-6172-801X
Mitsuru WatanabeDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0003-0831-623X
Sabine SchaedelinDepartment of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0002-1150-0962
Fredrik PiehlClinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-8329-5219
Roberto FurlanDivision of Neuroscience, Institute of Experimental Neurology, San Raffaele Hospital, Milan, Italy.ORCID 0000-0001-7376-9425
Matteo GastaldiLaboratory of Neuroimmunology, National Neurological Institute C. Mondino, Pavia, Italy.ORCID 0000-0003-2288-2000
Jeremy LambertQuanterix Corp, Lexington, Massachusetts, USA.
Björn EvertssonClinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-8799-9619
Katharina FinkClinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-0030-0236
Takuya MatsushitaDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Katsuhisa MasakiDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0003-2516-1102
Noriko IsobeDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0001-9525-4254
Jun-Ichi KiraDepartment of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0001-5307-2671
Pascal BenkertDepartment of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0001-6525-8174
Aleksandra MaceskiDepartments of Medicine, Biomedicine and Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0002-1916-5927
Eline WillemseDepartment of Neurology, Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0001-9140-4243
Johanna OechteringDepartment of Neurology, Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0001-5359-7961
Annette OrlethDepartment of Neurology, Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.
Stephanie MeierDepartment of Neurology, Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0002-8106-4203
Jens KuhleDepartment of Neurology, Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel, University of Basel, Basel, Switzerland.ORCID 0000-0002-6963-8892
University of Basel · CHKyushu University · JPKarolinska Institutet · SEFondazione Istituto Neurologico Nazionale Casimiro Mondino · ITNeuroscience Institute · ITQuanterix (United States) · US

Funding

Wellcome Trust FC001030
6 · The paper itself

Abstract

backgroundGranulocyte invasion into the brain is a pathoanatomical feature differentiating neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS). We aimed to determine whether granulocyte activation markers (GAM) in cerebrospinal fluid (CSF) can be used as a biomarker to distinguish NMOSD from MS, and whether levels associate with neurological impairment.

methodsWe quantified CSF levels of five GAM (neutrophil elastase, myeloperoxidase, neutrophil gelatinase-associated lipocalin, matrixmetalloproteinase-8, tissue inhibitor of metalloproteinase-1), as well as a set of inflammatory and tissue-destruction markers, known to be upregulated in NMOSD and MS (neurofilament light chain, glial fibrillary acidic protein, S100B, matrix metalloproteinase-9, intercellular adhesion molecule-1, vascular cellular adhesion molecule-1), in two cohorts of patients with mixed NMOSD and relapsing-remitting multiple sclerosis (RRMS).

resultsIn acute NMOSD, GAM and adhesion molecules, but not the other markers, were higher than in RRMS and correlated with actual clinical disability scores. Peak GAM levels occurred at the onset of NMOSD attacks, while they were stably low in MS, allowing to differentiate the two diseases for ≤21 days from onset of clinical exacerbation. Composites of GAM provided area under the curve values of 0.90-0.98 (specificity of 0.76-1.0, sensitivity of 0.87-1.0) to differentiate NMOSD from MS, including all anti-aquaporin-4 protein (aAQP4)-antibody-negative patients who were untreated.

conclusionsGAM composites represent a novel biomarker to reliably differentiate NMOSD from MS, including in aAQP4

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNeuromyelitis OpticaAquaporin 4BiomarkersHumansInflammationTissue Inhibitor of Metalloproteinase-1Aquaporin 4BiomarkersTissue Inhibitor of Metalloproteinase-1clinical neurologyCSFmolecular biologymultiple sclerosisneuroimmunology

Identifiers

PMID37076291
PMCPMC10447383
OpenAlexW4366386717

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.